CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma

PartnershipcliramitugPositive
AI Analysis

Summary

Neurimmune sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million ($125 million upfront), providing non-dilutive funding for the company.

Importance:6/10
Sentiment:
0.60
royalty_salenon-dilutive_fundingcliramitugNeurimmuneRoyalty_Pharma
Related Companies

Read the original article

Published by PR Newswire Biotech on July 22, 2026 10:50 AM

Read Original